Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Jun 30, 22 | 0.00 - | -539.76 K - |
Decreased by
N/A%
-
|
Mar 31, 22 | 0.00 - | -500.22 K - |
Decreased by
N/A%
-
|
Jun 30, 21 | 0.00 - | -47.82 K - |
Decreased by
N/A%
-
|
Mar 31, 21 | 0.00 - | -47.97 K - |
Decreased by
N/A%
-
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. Its lead products include Vaccine AV0328, a synthetic poly N-acetyl glucosamine (PNAG) vaccine that has completed Phase I first-in-man trial for the treatment of streptococcus pneumoniae, meningococcal infections, Alzheimer's disease, and type 1 diabetes mellitus; and F598, a monoclonal antibody that has completed Phase I and pilot Phase II trials for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units. The company is headquartered in Cambridge, Massachusetts.